• Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 214

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

2025 Year in Review: 10 Standout Stories in Psychedelics

2025 Year in Review: Looking Ahead to Psychedelics in 2026 (Video)

Oli Genn-Bash: Functional Mushrooms, Hype Cycles, and Mycelial Thinking

Chronic Pain, Illicit Markets, and a Preventable Pipeline to Addiction

Year in Review: Psychedelics in 2025 (Video)

Awakn Life Sciences Identifies New Chemical Series via Its Drug Discovery...

Cybin Announces Launch of EMBARK Psychedelic Facilitator Training Program

MYND Life Sciences Signs Agreement to Acquire Rights for the Use...

Entheon Biomedical Provides Corporate Update on Studies and Clinical Trials

Mydecine Reports Successful Synthesis of Novel Tryptamine Improving the Pharmaceutical Properties...

World Leading Drug Delivery Researcher Professor Ryan Donnelly Joins PharmaTher as...

Silo Pharma Enters into Sponsored Research Agreement with Columbia University to...

Nova Mentis Earns Psilocybin Orphan Drug Designation in Europe for Fragile...

MINDCURE Announces Financial Results for the First Quarter of Fiscal 2022

Cybin Announces FDA Investigational New Drug Authorization of Cybin’s Sponsored Feasibility...

1...213214215...305Page 214 of 305

EDITOR PICKS

2025 Year in Review: 10 Standout Stories in Psychedelics

2025 Year in Review: Looking Ahead to Psychedelics in 2026 (Video)

Oli Genn-Bash: Functional Mushrooms, Hype Cycles, and Mycelial Thinking

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    ©